UNSPSC 51422370: Flumetasone or flumethasone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28F2O5, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier LR3CD8SX89, chemically known as 6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione but more generally known as flumetasone, which bears U.S. NIH Compound Identifier 16490. European Medicines Agency schedules Flumetasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07698MIG.

UNSPSC 51422370 Flumetasone or flumethasone is a Commodity code that appears to see minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single recent opportunity identified under this code—Seminole County, Florida's IFB for naloxone and drug deactivation systems—involves emergency medical supplies rather than the corticosteroid medication the code describes, indicating a potential tagging mismatch in state and local procurement databases.

Seminole County Community Health posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county health building in Sanford. The solicitation requires electronic bid submission through the county's e-Procurement Portal, with shipping and delivery costs included in pricing; vendors must meet E-Verify and drug-free workplace certification requirements and maintain workers' compensation, commercial general liability, and professional liability insurance. The initial contract term runs two years with an optional one-year renewal, and the procurement may be funded through FEMA, subjecting vendors to federal environmental compliance audits and record inspection. Absent further recent opportunities under this code from other state or local issuing bodies, activity appears limited and primarily driven by emergency-response or opioid-mitigation initiatives in this jurisdiction rather than representing broader state and local demand for the pharmaceutical product the code nominates.